Boehringer Ingelheim grows faster than the pharmaceutical market for the tenth time in succession / continued high level of investment in R & D / market launch of five innovativ...

Wed, 04/21/2010 - 1:25pm
Boehringer Ingelheim

Ingelheim, 20 April 2010 – Boehringer Ingelheim continued to grow in 2009, increasing its net sales by 9.7% to EUR 12.7 billion (2008: EUR 11.6 billion). This was announced today by the company at its Annual Press Conference. Even without taking into account positive currency effects, growth was once again above the average growth for the worldwide pharmaceutical market, at 6.7%. This means that for the tenth consecutive time Boehringer Ingelheim grew faster than the pharmaceutical market and in 2009 was the fastest growing company of the world’s 15 largest pharmaceutical companies.
Operating income, comparable to EBIT, rose to EUR 2.2 billion, despite higher investments planned for research and development.
Professor Andreas Barner, Chairman of the Board of Managing Directors and responsible for the Corporate Board Division Research & Development and Medicine, expressed his satisfaction with the 2009 business year: "In view of the difficult economic environment, we believe that the success of 2009 confirms that our entrepreneurial approach was right. The success of our innovative medicines for patients and our promising research pipeline give us cause to be optimistic about the future."



Share this Story

You may login with either your assigned username or your e-mail address.
The password field is case sensitive.